{"id":9410,"date":"2021-04-26T09:54:56","date_gmt":"2021-04-26T16:54:56","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9410"},"modified":"2021-04-28T09:55:39","modified_gmt":"2021-04-28T16:55:39","slug":"covid-19-vaccine-coverage-in-health-care-workers-in-england-and-effectiveness-of-bnt162b2-mrna-vaccine-against-infection-siren-a-prospective-multicentre-cohort-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/26\/covid-19-vaccine-coverage-in-health-care-workers-in-england-and-effectiveness-of-bnt162b2-mrna-vaccine-against-infection-siren-a-prospective-multicentre-cohort-study\/","title":{"rendered":"COVID-19 Vaccine Coverage in Health-Care Workers in England and Effectiveness of BNT162b2 MRNA Vaccine against Infection (SIREN): A Prospective, Multicentre, Cohort Study"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The Pfizer-BioNTech vaccine showed <\/span><span style=\"font-weight: 400\">70% effectiveness against SARS-CoV-2 infection 21 days after <\/span><span style=\"font-weight: 400\">the <\/span><span style=\"font-weight: 400\">first dose, and 85% effectiveness 7 days after two doses among staff working in publicly-funded hospitals in the UK. Participants were followed for two months, for a total of 1<\/span><span style=\"font-weight: 400\">,<\/span><span style=\"font-weight: 400\">106<\/span><span style=\"font-weight: 400\">,<\/span><span style=\"font-weight: 400\">905 person-days. During follow-up, 977 new infections occurred among unvaccinated individuals (14 per 10<\/span><span style=\"font-weight: 400\">,<\/span><span style=\"font-weight: 400\">000 person-days), compared to 71 infections 21 <\/span><span style=\"font-weight: 400\">or more <\/span><span style=\"font-weight: 400\">days after dose 1 in the vaccinated group (8 per 10<\/span><span style=\"font-weight: 400\">,<\/span><span style=\"font-weight: 400\">000 person-days) and 9 infections one week after the second dose (4 per 10<\/span><span style=\"font-weight: 400\">,<\/span><span style=\"font-weight: 400\">000 person-days).\u00a0Among unvaccinated individuals who were infected, 543 (56%) had typical COVID-19 symptoms and 140 (14%) were asymptomatic <\/span><span style=\"font-weight: 400\">within 1<\/span><span style=\"font-weight: 400\">4 days <\/span><span style=\"font-weight: 400\">of <\/span><span style=\"font-weight: 400\">testing positive, compared with infections in the vaccinated cohort, where 29 (36%) individuals had typical COVID-19 symptoms and 15 (19%) were asymptomatic.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Hall et al.\u00a0(Apr 26, 2021). COVID-19 Vaccine Coverage in Health-Care Workers in England and Effectiveness of BNT162b2 MRNA Vaccine against Infection (SIREN): A Prospective, Multicentre, Cohort Study. The Lancet. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)00790-X\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S0140-6736(21)00790-X<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Pfizer-BioNTech vaccine showed 70% effectiveness against SARS-CoV-2 infection 21 days after the first dose, and 85% effectiveness 7 days after two doses among staff working in publicly-funded hospitals in the UK. Participants were followed for two months, for a total of 1,106,905 person-days. During follow-up, 977 new infections occurred among unvaccinated individuals (14 per&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/26\/covid-19-vaccine-coverage-in-health-care-workers-in-england-and-effectiveness-of-bnt162b2-mrna-vaccine-against-infection-siren-a-prospective-multicentre-cohort-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[32,147],"topic":[31],"class_list":["post-9410","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immunity","tag-vaccination","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9410"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9410\/revisions"}],"predecessor-version":[{"id":9411,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9410\/revisions\/9411"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9410"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}